? CLINICAL-TRANSLATIONAL SCIENCE SHARED RESOURCE (CTSSR) The goal of the CTSSR is to foster the clinical-translational mission of OSUCCC members without wet- laboratories by providing support and short-term needs for correlative science and other testable hypotheses. The CTSSR is a consultative project management and central laboratory service that was developed with a focus on investigator-initiated solid tumor clinical trials, but now supports all types of dry laboratory researchers (hematological malignancy and population scientists). During the current funding cycle, the CTSSR, formerly known as the Solid Tumor Translational developing Shared Resource (SR) was funded through CCSG development funds, and is now being proposed as a full CCSG SR.
The Specific Aims of the CTSSR are to: 1) provide project design and project management support (including navigation, protocol development, grant application and manuscript preparation) for studies that utilize resources available through other OSUCCC SRs, investigator laboratories, and outside vendors; 2) provide specific laboratory services and sample processing support for clinical translational research; and, 3) develop and rigorously perform customized laboratory assays to meet the short-term needs of clinical investigators for a specific protocol, a specified time, or a specified number of patient samples. Conveniently located within the Biomedical Research Tower, the CTSSR is accessible to most OSUCCC clinicians and tissue procurement services. Major equipment includes a cell culture facility, a QX200 Droplet Digital PCR System-Bio Rad and a Promega Maxwell RSC for high throughput nucleic acid purification, and a Luminex Magpix for multiplex protein assays. During the current grant period, the CTSSR has supported 94 investigators (62% OSUCCC members), and provided 8,223 hours of service and processed 3,602 samples (82.9% to OSUCCC members). The CTSSR provided services in support of 72 publications (14 > 10 impact factor), 94 users, and 9 NCI grants, including 1 K01, 2 P01s, 1 P50, 4 R01s, and 1 R03. The CTSSR currently supports 20 ongoing trials and there are 8 new ones in the pipeline (spanning all five programs). It is anticipated that the CTSSR will expand rapidly due to the continued rapid growth of the OSUCCC with its strategic priorities. Specific future plans include participating in the developing Immune Monitoring and Discovery Platform, fostering interactions with other shared resources for immuno-oncology projects; increase support for hematologic and population science studies; establish a cell culture facility to enable preclinical cancer cell culture studies (including drug synergy) needed as pilot data for human studies applications; and provide multiplex protein arrays for human studies using whole cells, cell/tumor extracts and other biological fluids. The annual budget of the CTSSR is $552,510, yet the CCSG request is $60,723. As such, The CTSSR leverages extensive institutional support and seeks only 11% support from CCSG funds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090007
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Fu, Xinping; Tao, Lihua; Wang, Pin-Yi et al. (2018) Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget 9:21348-21358
Brewington, Beatrice Y; Shao, Yusra F; Davidorf, Fredrick H et al. (2018) Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions. Clin Ophthalmol 12:925-934
Doogan, Nathan J; Cooper, Sarah; Quisenberry, Amanda J et al. (2018) The role of travel distance and price promotions in tobacco product purchase quantity. Health Place 51:151-157
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
Oblinger, Janet L; Burns, Sarah S; Huang, Jie et al. (2018) Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol 299:299-307
Shu, Yi; Yin, Hongran; Rajabi, Mehdi et al. (2018) RNA-based micelles: A novel platform for paclitaxel loading and delivery. J Control Release 276:17-29
Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Schimizzi, Gregory V; Jin, Linda X; Davidson 4th, Jesse T et al. (2018) Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford) 20:332-339
Wang, Yufeng; Dong, Wenjuan; Zhang, Yibo et al. (2018) Dependence of innate lymphoid cell 1 development on NKp46. PLoS Biol 16:e2004867

Showing the most recent 10 out of 2602 publications